Ferguson GT, et al. - This study entailed an assessment of at-home functionality, reliability, and performance of an accessorized pre-filled syringe (APFS) for subcutaneous benralizumab (an anti-eosinophil monoclonal antibody) administration in patients (N=116) with severe, uncontrolled asthma despite receiving medium- or high-dosage inhaled corticosteroids and long-acting β₂-agonists. Of 573 APFS dispensed, only 1 malfunctioned. This treatment resulted in decreased mean Asthma Control Questionnaire 6 scores from baseline through all post-baseline time points. At the end of treatment, nearly complete depletion of eosinophils was observed. Nasopharyngitis, upper respiratory tract infection, headache, and sinusitis were documented as the most common adverse events. Overall, APFS was shown to be functional, reliable, and performed equally well in the clinic and at home.